Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures

Разработка технологии вирусоподобных частиц от небольших высоко симметричных до крупных сложных структур вирусоподобных частиц
Peter Pushko, Paul Pumpens, Elmars Grens
2013-01-01

HPV vaccination recommendations (ACIP)HPV-associated diseases and burdenhuman papillomavirus vaccine (HPV4)quadrivalent HPV vaccinevirus-like particle technology
On October 16, 2009, the Food and Drug Administration licensed quadrivalent human papillomavirus vaccine (HPV4; Gardasil, Merck & Co. Inc.) for use in males aged 9 through 26 years for prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11. HPV4 had been licensed previously for use in females aged 9 through 26 years for prevention of HPV 6, 11, 16, and 18-related outcomes (i.e., vaginal, vulvar, and cervical precancers and cancers and genital warts). The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of females at age 11 or 12 years and catch-up vaccination for females aged 13 through 26 years. On October 21, 2009, ACIP provided guidance that HPV4 may be given to males aged 9 through 26 years to reduce their likelihood of acquiring genital warts; ACIP does not recommend HPV4 for routine use among males. This report presents the ACIP policy statement and summarizes background data. Issues reviewed by ACIP included efficacy, immunogenicity, and safety of the HPV4 vaccine in males, epidemiology of HPV and burden of HPV-associated diseases and cancers in males, cost-effectiveness of male vaccination, and programmatic considerations.
1
ACIP recommends routine HPV vaccination for females at age 11–12 with catch-up vaccination for females aged 13–26.
2
ACIP reviewed male-specific data on vaccine efficacy, immunogenicity, safety, HPV epidemiology and disease burden in males, cost-effectiveness, and programmatic considerations when forming the policy.
3
HPV4 was previously licensed for females aged 9–26 to prevent HPV 6, 11, 16, and 18-related outcomes including vaginal, vulvar, and cervical precancers, cancers, and genital warts.
4
On October 16, 2009 the FDA licensed the quadrivalent HPV vaccine (HPV4; Gardasil) for males aged 9–26 to prevent genital warts caused by HPV types 6 and 11.
5
On October 21, 2009 ACIP advised that HPV4 may be given to males aged 9–26 to reduce genital wart acquisition but did not recommend routine use among males.

Virus-like particles (VLP) technology and virus-like particle structures

Development and scaling of VLP technology from small highly symmetric to large complex VLP structures, including implications for vaccine design and immunogenicity

Publication Details
Publication Date
2013-01-01
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Peter Pushko
Paul Pumpens
Elmars Grens
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%